FDA Reconsiders Ebvallo for Rare Cancer
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Pierre Fabre Pharmaceuticals and Atara Biotherapeutics reached an agreement with the FDA that their completed single-arm clinical trial supports a new review for Ebvallo approval
- FDA reversed its January decision that the Ebvallo trial data were 'insufficient,' now accepting the study design as potentially adequate for approval
- Vinay Prasad, head of the FDA’s Center for Biologics Evaluation and Research, departed the agency at the end of April, shortly after the Ebvallo rejection and before the reevaluation
Why it matters: Patients with rare blood cancers could gain access to Ebvallo months earlier than expected if the FDA approves it based on the existing trial, while the agency's reversal signals potential shifts in regulatory standards under new leadership.
